A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 166 participants.
Also called NCT06635057
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 166 participants
- Sponsor
- Registry
-
NCT06635057
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Saudi Arabia, United Arab Emirates
- Registry status
- Completed
Technical summary
Registry record NCT06635057. Allocation not applicable; no masking; primary purpose treatment. Start 2024-10-11 (actual); primary completion 2026-04-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan
- Acronym
- T-RAM
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Tirzepatide
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct06635057- Content hash
cdfbbe4e4fad407660e919a07698d5b15f0ac29ec555b906420fbf83946d3abf